» Articles » PMID: 33237727

Biomimetic Virus-Like Particles As Severe Acute Respiratory Syndrome Coronavirus 2 Diagnostic Tools

Overview
Journal ACS Nano
Specialty Biotechnology
Date 2020 Nov 25
PMID 33237727
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Coronavirus disease 2019 (COVID-19) is a highly transmissible disease that has affected more than 90% of the countries worldwide. At least 17 million individuals have been infected, and some countries are still battling first or second waves of the pandemic. Nucleic acid tests, especially reverse transcription polymerase chain reaction (RT-PCR), have become the workhorse for early detection of COVID-19 infection. Positive controls for the molecular assays have been developed to validate each test and to provide high accuracy. However, most available positive controls require cold-chain distribution and cannot serve as full-process control. To overcome these shortcomings, we report the production of biomimetic virus-like particles (VLPs) as SARS-CoV-2 positive controls. A SARS-CoV-2 detection module for RT-PCR was encapsidated into VLPs from a bacteriophage and a plant virus. The chimeric VLPs were obtained either by reconstitution and coexpression of the target detection module and coat proteins or by assembly of purified detection module RNA sequences and coat proteins. These VLP-based positive controls mimic SARS-CoV-2 packaged ribonucleic acid (RNA) while being noninfectious. Most importantly, we demonstrated that the positive controls are scalable, stable, and can serve broadly as controls, from RNA extraction to PCR in clinical settings.

Citing Articles

The RNA Landscape of In Vivo-Assembled MS2 Virus-Like Particles as mRNA Carriers Reveals RNA Contamination from Host Viruses.

Ma C, Yang M, Zhou W, Guo S, Zhang H, Gong J Nano Lett. 2025; 25(8):3038-3044.

PMID: 39932477 PMC: 11869999. DOI: 10.1021/acs.nanolett.4c04541.


Enhanced efficacy of a TLR3 agonist delivered by cowpea chlorotic mottle virus nanoparticles.

Jung E, Foroughishafiei A, Chung Y, Steinmetz N Small Sci. 2024; 4(7).

PMID: 39640945 PMC: 11615967. DOI: 10.1002/smsc.202300314.


Strengths and limitations of SARS-CoV-2 virus-like particle systems.

Sultana R, Stahelin R Virology. 2024; 601:110285.

PMID: 39536645 PMC: 11624109. DOI: 10.1016/j.virol.2024.110285.


Bacteriophage Virus-Like Particles: Platforms for Vaccine Design.

Tumban E Methods Mol Biol. 2023; 2738:411-423.

PMID: 37966612 DOI: 10.1007/978-1-0716-3549-0_24.


TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy.

Jung E, Chung Y, Steinmetz N Bioconjug Chem. 2023; 34(9):1596-1605.

PMID: 37611278 PMC: 10538388. DOI: 10.1021/acs.bioconjchem.3c00271.